FDA
approval
· 2023-01-04
FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
Summary
FDA indicates a supplemental application for COPAXONE (glatiramer acetate) by Teva Neuroscience, Inc. has been approved.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for COPAXONE (GLATIRAMER ACETATE)